Preprint / Version 1

IMMUNOHISTOCHEMICAL ANALYSIS OF THE CYCLIN D1 BIOMARKER IN PAPILLIFEROUS THYROID CARCINOMAS AND MULTINODULAR GOITERS

##article.authors##

  • Ivan José Paredes Bartolomei Faculdade Evangélica Mackenzie do Paraná
  • Carmen Austrália Paredes Marcondes Ribas Faculdade Evangélica Mackenzie do Paraná
  • Maria Augusta Karas Zella Faculdade Evangélica Mackenzie do Paraná
  • Ana Maria Waaga-Gasser Brigham and Women's Hospital image/svg+xml
  • Martin Gasser Faculdade Evangélica Mackenzie do Paraná
  • Nicolau Gregori Czeczko Faculdade Evangélica Mackenzie do Paraná
  • Paulo Afonso Nunes Nassif Faculdade Evangélica Mackenzie do Paraná https://orcid.org/0000-0002-1752-5837

DOI:

https://doi.org/10.1590/SciELOPreprints.4150

Keywords:

Papillary thyroid carcinomas, Cyclin D1, Immunohistochemistry

Abstract

Background: Papillary thyroid carcinomas (PTC) are the most prevalent and least aggressive thyroid carcinomas. In some cases, the diagnosis is doubtfull and the prognosis is poor. The search for tissue biomarkers that make it possible to ensure both the diagnosis for indeterminate cases and the prognosis, identifying the most aggressive cases, has been studied in recent decades. Objective: To analyze the molecular marker cyclin D1 in PTC and multinodular goiter (BMN) and to verify the correlation of the marking with the clinical-pathological characteristics in carcinomas. Methods: 118 tissues from adult patients submitted to PTC thyroidectomy and 40 BMN were selected as a control group. Tissue immunostaining was performed with cyclin D1 with subsequent immunohistochemical analysis in both groups, evaluating the expression of the marker (intensity and distribution). In the PTC group, immunostaining data were also crossed with clinical and pathological data. Results: The majority (93.3%) expressed the staining of cyclin D1 with varying intensities (weak, moderate 3 and strong) and predominantly diffuse distribution (71.2%). The BMN control group expressed staining for cyclin D1 in 57.5%, with weak intensity (47.5%) and sparse distribution (37.5%). The difference between the groups (study and control) was statistically significant (p<0.001). In the CPT group, the clinical-pathological crossings did not show differences regarding age, sex, tumor type and size, lymph node status, focus, angiolymphatic invasion. Conclusion: Cyclin D1 was expressed in the vast majority of PTC with the predominant diffuse distribution. There was no correlation between the expression of cyclin D1 and any clinical-pathological characteristic of PTC.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Posted

05/20/2022

How to Cite

Bartolomei, I. J. P., Ribas, C. A. P. M., Zella, M. A. K., Waaga-Gasser, A. M., Gasser, M., Czeczko, N. G., & Nassif, P. A. N. (2022). IMMUNOHISTOCHEMICAL ANALYSIS OF THE CYCLIN D1 BIOMARKER IN PAPILLIFEROUS THYROID CARCINOMAS AND MULTINODULAR GOITERS. In SciELO Preprints. https://doi.org/10.1590/SciELOPreprints.4150

Section

Health Sciences
0 Rapid PREreviews
0 Full PREreviews
1 Request

View on the PREreview website